SCHEDULE: Weiss Asset Management Discloses 5.4% Stake in scPharmaceuticals

Weiss Asset Management LP, along with WAM GP LLC and Andrew M. Weiss, has reported a 5.4% beneficial ownership stake in scPharmaceuticals Inc. common stock.

Summary

• Weiss Asset Management LP, WAM GP LLC, and Andrew M. Weiss collectively reported beneficial ownership of 2,881,669 shares of scPharmaceuticals Inc. common stock.
• This ownership represents 5.4% of the total outstanding common stock of scPharmaceuticals Inc.
• The reporting persons hold shared voting power and shared dispositive power over all 2,881,669 shares.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer, except for activities solely in connection with a nomination under Rule 240.14a-11.
• The percentage of class calculation is based on 53,761,939 shares of Common Stock outstanding as of September 2, 2025, as reported in scPharmaceuticals Inc.'s Form SC 14D9 filed on September 8, 2025.

Sentiment

Score: 6

Explanation: The disclosure of a 5.4% beneficial ownership by Weiss Asset Management LP, a known investment firm, in scPharmaceuticals Inc. is a moderately positive signal, indicating institutional interest and potential confidence in the company's value or future prospects. The statement that the shares are held in the ordinary course of business and not for control purposes suggests a long-term investment horizon.

Positives

• A significant institutional investor, Weiss Asset Management, has taken a 5.4% stake in scPharmaceuticals Inc., potentially signaling confidence in the company's prospects.
• The investment is stated to be in the ordinary course of business, suggesting a long-term investment strategy rather than an activist play for control, which can provide stability.

Risks

• The filing does not explicitly mention risks related to scPharmaceuticals Inc. The standard certification states the shares were not acquired for the purpose of changing or influencing control, which mitigates a common risk associated with large stakes (activist intervention).

Future Outlook

Not applicable. This filing is a disclosure of past/current ownership and does not contain forward-looking statements or guidance from the issuer or the reporting persons regarding the issuer's future performance.

Industry Context

Not applicable. This filing is a specific ownership disclosure and does not provide analysis of broader industry trends or competitors.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor taking a 5.4% stake could be viewed positively, potentially increasing investor confidence and liquidity.
• Company Management: Awareness of a significant institutional shareholder may influence strategic decisions or communication.

Key Dates

Recommendation

This Schedule 13G filing primarily discloses a significant ownership stake by Weiss Asset Management LP in scPharmaceuticals Inc. While the acquisition of a 5.4% stake by an institutional investor can be seen as a positive signal of confidence, the filing itself does not provide sufficient financial or operational details to warrant a 'buy' or 'sell' recommendation. It suggests institutional interest, which might support the stock, but without further analysis of scPharmaceuticals' fundamentals, a 'hold' recommendation is prudent, advising investors to maintain their current position while awaiting more comprehensive company updates.

Keywords

scPharmaceuticals, Weiss Asset Management, WAM GP, Andrew M. Weiss, Common Stock, SEC filing, Schedule 13G, beneficial ownership, institutional investment, pharmaceutical, biotech